Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology


  1. Published

    Bone marrow toxicity and immune reconstitution in melanoma and non-melanoma solid cancer patients after non-myeloablative conditioning with chemotherapy and checkpoint inhibition

    Kverneland, Anders Handrup, Borch, T. H., Granhøj, J., Sengeløv, Henrik, Donia, M. & Svane, Inge Marie, Aug 2021, In: Cytotherapy. 23, 8, p. 724-729 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    Broadening the repertoire of melanoma-associated T-cell epitopes

    Frøsig, T. M., Lyngaa, R., Met, Özcan, Larsen, S. K., Donia, M., Svane, Inge Marie, Thor Straten, P. & Hadrup, S. R., May 2015, In: Cancer immunology, immunotherapy : CII. 64, 5, p. 609-20 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment

    Martinenaite, E., Munir Ahmad, S., Hansen, M., Met, Özcan, Westergaard, M. W., Larsen, S. K., Klausen, T. W., Donia, M., Svane, Inge Marie & Andersen, Mads Hald, 2016, In: OncoImmunology. 5, 11, 10 p., e1238541.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53

    Sørensen, R. B., Andersen, R. S., Svane, Inge Marie, Engell-Noerregaard, L., Hadrup, S. R., Balslev, E., Andersen, Mads Hald & thor Straten, P., 2009, In: Clinical Cancer Research. 15, 5, p. 1543-9 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

    Holmstroem, R. B., Nielsen, Ole Haagen, Jacobsen, Søren, Riis, Lene Buhl, Theile, S., Bjerrum, Jakob Tveiten , Vilmann, Peter, Johansen, Julia Sidenius, Boisen, M. K., Eefsen, R. H. L., Svane, Inge Marie, Nielsen, Dorte Lisbet & Chen, I. M., 2022, In: Journal for ImmunoTherapy of Cancer. 10, 9

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer

    Friese, C., Harbst, K., Borch, T. H., Westergaard, M. C. W., Pedersen, M., Kverneland, A., Jönsson, G., dqp123, dqp123, Svane, Inge Marie & Met, Özcan, 2020, In: Scientific Reports. 10, 1, 12 p., 3914.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer

    Kongsted, P., Svane, Inge Marie, Lindberg, H., Bisbjerg, R., Daugaard, G. & Sengeløv, L., Aug 2016, In: Anti-Cancer Drugs. 27, 7, p. 695-701 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Cancer immunotherapy in patients with brain metastases

    Caponnetto, S., Draghi, A., Borch, T. H., Nuti, M., Cortesi, E., Svane, Inge Marie & dqp123, dqp123, 2018, In: Cancer Immunology, Immunotherapy. 67, 5, p. 703-711 9 p.

    Research output: Contribution to journalReviewResearchpeer-review

  9. Published

    Cancer immunotherapy in patients with preexisting autoimmune disorders

    dqp123, dqp123, Pedersen, M. & Svane, Inge Marie, Apr 2017, In: Seminars in Immunopathology. 39, 3, p. 333-337 5 p.

    Research output: Contribution to journalReviewResearchpeer-review

  10. Published

    Cancer treatment: the combination of vaccination with other therapies

    Andersen, M. H., Sorensen, R. B., Schrama, D., Becker, J. C., Straten, P. T. & Svane, Inge Marie, 2008, In: Cancer Immunology, Immunotherapy. 57, 11, p. 1735-1743 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...28 Next

ID: 4054758